Flow Injection Chemiluminescence Method for Nalbuphine Hydrochloride in Pharmaceutical Formulations Using Tris(2,2′-bipyridyl)ruthenium(II) Chloride-diperiodatocuprate(III) Reaction

Construction of novel potentiometric sensors modified with biogenically synthesized metal oxide nanoparticles for sensitive detection of the opioid agonist-antagonist nalbuphine hydrochloride in its injection

Novel and sensitive potentiometric sensors were described for the assay of nalbuphine HCl (NBP) in authentic powder and injection samples. The developed sensors were modified with alumina nanoparticles (Al2O3NPs) and copper oxide nanoparticles (CuONPs). The nanoscale materials were synthesized using the extract of Salvia officinalis leaves in an environmentally friendly manner. The synthesized metal oxides were fully confirmed by various analytical techniques. Scanning electron microscope confirmed the morphology of nanosized materials with even distribution and particle size of 55.07 ± 4.15 and 59.48 ± 4.50 nm for Al2O3NPs and CuONPs, respectively. The modified sensors were prepared in three different steps. Nalbuphine hydrochloride was mixed with phosphomolybdic acid to prepare the sensor material nalbuphine phosphomolybdate (NBP-PM). It was then mixed with polyvinyl chloride in the presence of o-nitrophenyl ether and metal oxide nanoparticles to form the membrane matrix. Finally, a copper wire was coated with the sensing material. Excellent potentials of 1.0 × 10-8-1.0 × 10-2 and 1.0 × 10-9-1.0 × 10-2 mol L-1 were measured with lower assay limits of 4.8 × 10-9 and 5.0 × 10-10 mol L-1. The average detection % were 99.28 ± 0.58% and 99.52 ± 0.28% for NBP-PM-Al2O3NPs and NBP-PM-CuONPs, correspondingly. The suitability of the described sensors was investigated in terms of various validation criteria, and the modified sensors exposed excellent applicability and insurance for the quantification of nalbuphine hydrochloride in its bulk samples and injections compared with another standard sensor. It is obvious that the developed NBP-PM-Al2O3NPs and NBP-PM-CuONPs will serve as suitable sensors for the determination of NBP.

Eco-friendly fluorimetric approaches for the simultaneous estimation of the co-administered ternary mixture: etoposide, moxifloxacin and nalbuphine

Antineoplastic drugs, etoposide (ETO), are widely used in leukaemia. A patient with leukaemia has a relative infection with pneumonia treated by fluoroquinolones as moxifloxacin HCL (MOX). Because opioid analgesic as nalbuphine HCL (NAL) does not have a ceiling dose, it is used to manage the distasteful sensory in leukaemia. Consequently, green methods for synchronous spectrofluorimetric quantification of a ternary mixture of ETO, MOX and NAL were developed. The first approach relies simply on the estimation of MOX at 371 nm by conventional synchronous fluorimetric technique (Δλ of 60 nm). The second approach depends on applying the first derivative synchronous fluorimetric technique (Δλ of 60 nm) for simultaneous estimation of ETO and NAL at 257 and 273 nm, respectively. A good linear correlation was obtained in the ranges of 0.04-0.40, 0.10-1.00 and 0.50-5.00 µg ml-1 for MOX, ETO and NAL, respectively. Moreover, the proposed approaches were successfully applied for the estimation of the studied drugs in the pharmaceutical dosage forms. Additionally, the synchronous assessment of ETO, MOX and NAL in the spiked human urine was successfully attained by the facile protein precipitation technique. The mean % recoveries in spiked human urine were 99.49, 98.07 and 98.48 for MOX, ETO and NAL, respectively.